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Abstract

As many as 25% of the population age 60 years and older
may be affected by onychomycosis,

a chronic infection that

is difficult to cure. Onychomycosis can cause pain and
soft tissue injury that can lead to infection affecting
gait from discomfort.

Current oral medications available

for the treatment of onychomycosis are costly and can pose
the risk of serious side effects.

The purpose of this

study was to determine if the use of Mentholatum was an
effective and cost-efficient means to treat onychomycosis
of the toenail in elders.

The Neuman Systems Model was

used as the theoretical framework:

specifically,

Neuman's

secondary prevention interventions to support system
stabilization.

The null hypothesis of this study was

stated as follows : There will be no effect on the
onychomycosis of the toenails in the elderly treated with
Mentholatum. A quasi-experimental design was used to
compare photographs of the toenail prior to treatment and
photographs of the toenail at completion of the treatment.
The subjects were drawn from three nursing homes in a
southern state.

Permission was obtained from residents and
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their responsible party for participation in the study.
The 33 subjects ranged from 65 to 96 years.

The

Mentholatum was applied twice daily by a nurse researcher
assistant.

Digital photographs of the elder's toe were

graded by a panel of experts,
podiatrist.

three physicians and a

The nail changes were graded on a 5-point

Likert scale.

The outcomes of the study revealed 90% of

the subjects experienced some positive change in the nail
growth,

which indicated a statistical significance.

Therefore,

the null hypothesis was rejected.

the limitation in the length of the study,

there was no

determination if nail cure could be achieved.
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Chapter I
The Research Problem

Onychomycosis is a fungal nail infection which is
known to be difficult to treat and can frequently have a
negative impact on one's quality of life

(Drake,

Although onychomycosis can be asymptomatic,
symptomatic,
discomfort,

the thickened,
pain,

1997).

if

dystrophic nails can result in

soft tissue injury,

and infection.

Onychomycosis accounts for 60% of consultations for nail
disorders

(Havu et al.,

2000). Onychomycosis is the nail

disease most commonly encountered by clinicians
Ryder,

2002).

Gupta and Ryder

(2002)

(Gupta &

reported 2% to 18% of

the population is affected by onychomycosis,

with higher

prevalence in those ages 60 years and older,

diabetic,

or

HIV positive.
Because of increased use of alternative approaches by
American citizens to both treat illness and promote
health,

the President of the United States in 2000 issued

an executive order for the formation of a commission to
develop policy recommendations on complementary and
alternative medicine

(CAM). The White House Commission
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recognized the need for scientific research to determine
which CAM practices were "clinically effective and costeffective"

(White House Commission on Complementary and

Alternative Medicine,

2003,

f l 7 ) . The purpose of this

research was to evaluate the effectiveness of Mentholatum
as an alternative treatment for onychomycosis of the
toenail in the elderly.

Establishment of the Problem
Onychomycosis occurs when the nail or nail bed is
infected by fungi or yeast.

The organism enters the

hyponychium from the surrounding skin, producing
inflammation,
onycholysis.

which results in hyperkeratosis and
The combined effects of the detachment of the

plate from the nail bed and subungual thickening often
produce discomfort as well as potentially serious
complications for vulnerable adults
2001).

Schein et al.

(1997)

(Rodgers & Bassler,

reported 54% of the patients

with onychomycosis experienced discomfort.

Bending

(2002)

stated approximately one third of fungal skin infections
are related to onychomycosis and predicted an increase of
onychomycosis due to an aging population and a greater
number of people who are immunocompromised.
Onychomycosis affects the quality of life of those
who are afflicted with the disease.

Guttman

(2002)

3
reported onychomycosis'

"greatest impact on the quality of

life were for emotions,

followed by symptoms,

function"

(Guttman,

and then

2002, p. Sll). Contributing factors to

the emotional impact were concerns the disease would
worsen,
2002).

shame,

frustration,

and embarrassment

(Guttman,

This finding was supported by Schein et al.

(1997),

who reported 67% of the patients with onychomycosis
experienced embarrassment related to the nail's appearance
and 40% of the patients were limited in their choice of
shoes.
The prevalence of onychomycosis varied among reports.
Roberts

(1992)

estimated an incidence of 2.8% in males and

2.6% in female patients,

whereas Heikkila and Stubbs

(1995)

estimated 8.4% of the population,

(2000)

reported 16.7% of patients had abnormal nails with

8% mycologically confirmed onychomycosis.

and Gupta et al.

While the

prevalence of onychomycosis varied by study,

all

researchers reported greater incidence in m a l e s .
The prevalence of onychomycosis with a co-morbidity
was evaluated by Ramano,
(2001)

Massai, Asta,

and Signorini

who reported a 6% dermatophyte nail infection in

patients with diabetes mellitus,
and MacDonald

(1998)

Konnikov,

estimated one third of diabetics will

develop onychomycosis,
and Monroy-Ramos

while Gupta,

(2001)

de Ocariz, Arenas,

Ranero- Ju ar ez ,

reported nail changes were present
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in 16.11% of patients with a venous leg ulcer,
the nail changes attributed to onychomycosis.

with 59% of
This high

incidence among patients with vascular disease was
confirmed by Gupta et al.
with vascular disease,

(2002)

in 4 9.2% of the patients

22.4% of the nail changes were

onychomycosis confirmed by mycology.
Lynde,

and Jain

(1997)

Further,

Gupta,

reported 27% of patients with

psoriasis and abnormal nails had onychomycosis.
The cost for the treatment of dermatophyte toenail
onychomycosis in the United States as reported by Gupta
(2002)

is griseofulvin

(Fulvicin,

Grifulvin V)

at a dose

of 500 mg twice daily for 12 months at $1,072.80 with the
additional cost of consultation,

return visits,

mycological exam,

and laboratory testing

additional costs)

of $396;

itraconazole

(referred to as
(Sporanox)

at a

dose of 200 mg a day for 12 weeks at $1,246.58 with the
additional costs totaling $215,

and terbinafine

(Lamisil)

at a dose of 250 mg a day for 12 weeks at $701.40 with the
additional costs totaling $245.
included,

Fluconazole

(Diflucan)

was

although it is not been approved for treatment

of onychomycosis,

at a dose of 150 mg weekly for 12 months

at $638.04 with additional costs totaling $366.

The

patient's systemic functions should be monitored with the
use of these drugs.

For example,

kidney function should be

monitored with the use of itraconazole and griseofulvin.
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liver function should be monitored with the use of
itraconazole and terbinafine,

and itraconazole should also

be monitored for congestive heart failure.
Because of the evidence that a significant number of
the population may be afflicted with onychomycosis,

the

nurse practitioner should be vigilant in the examination
of the patient's nails.

While discomfort and potential

risks of serious complications resulting from the
infection certainly warrant treatment,

the nurse

practitioner should consider cost, drug interactions in
patients in polypharmacy,

and the difficulties of

differential diagnosis for abnormal nails.

There is no

research into the alterative therapy of Mentholatum as a
treatment for onychomycosis.

If effective,

ointment will be able to reduce discomfort,

Mentholatum
which will

positively impact the quality of life and do so at a cost
less than traditional medication.

Significance to Nursing
The nurse practitioner approaches the whole person
when providing care. With the increased use of CAM,

the

nurse practitioner must be aware of what CAMs are and
their effects.

If the client utilizes CAM,

the nurse

practitioner should be able to give knowledgeable
information regarding safety and efficacy and aid the

6
client in health care decision making.

A supporting and

accepting atmosphere should be provided,

so that the nurse

practitioner and the client can explore if and how CAM and
traditional medicine could be blended.

It is essential

that the practitioner does not dismiss CAM as irrelevant
or noncontributory to the health of the client.

Such a

dismissal could result in the nurse practitioner reducing
the effectiveness of treatment and the willingness of the
client to seek treatment from that provider.

Research

concerning the efficacy of the alternative treatment of
onychomycosis with Mentholatum ointment will provide the
practitioner with information to aid clients in
determining their choice of treatment.

Theoretical Framework
The Neuman Systems Model has been selected for the
theoretical framework of this research.

The Neuman Systems

Model has its foundations in Gestalt's theory of an
organism maintaining homeostasis,

Bernard Marx's

philosophy of the parts are determined by the whole,
Pierre de Chardin's philosophy of life's wholeness,
Caplan's conceptual model of levels of prevention,
Seyle's definition of stress. Additionally,

and Han

Betty Neuman

utilized her own philosophies and experience to develop
the model

(Tomey & Alligood,

2002).

7
A wholistic approach for client care is utilized,

in

which the client's continuous adjustment to maintain
stability with the environment is assessed and
interventions are planned.

Neuman identified five

variables in man which interact with the environment:
psychological,

sociocultural,

physiological,

developmental,

and spiritual.

When stressors,

interpersonal or extrapersonal,

either

are introduced,

disharmony

of the system's parts may develop and illness ensues.
These stressors must penetrate the system's lines of
defense.

The normal life of defense is maintained by the

client and is utilized to resist deviations from wellness.
The flexible line of defense is the client's ability to
rapidly adjust to stressors to maintain wellness.

The

lines of resistance are those resources used to defend
against stressors

(Neuman,

1982).

The model also includes three levels of intervention
for a systematic approach,
have been identified.

once stressors are suspected or

The first level, primary prevention,

is implemented to support the client's flexible line of
defense so that stability may be maintained.
this study,

As related to

the client would need education regarding

proper shoe fit and nail and skin care of the foot.
second level is secondary prevention.
stress have developed,

The

Once symptoms of

the client's lines of resistance
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need strengthening to stabilize the system and reduce the
response to the stressors.

This study introduced an

intervention for onychomycosis,

which if effective,

is

less costly than the currently available traditional
treatments.

The final level,

tertiary prevention,

implemented after either level one or level two,

is
or both,

have been resolved and interventions are then implemented
to prevent recurrence.

Effectively treated onychomycosis

would be followed by continued education regarding proper
foot care and continued monitoring for relapse.

The client

and the nurse practitioner working collaboratively may be
at any and all of the levels at the same time in the
treatment and education of the client

(Neuman,

1982).

This study was concerned with secondary prevention.
In clients with onychomycosis,

lines of resistance have

been interrupted and disharmony has occurred.

Determining

the effects of Mentholatum on onychomycosis can provide
information that impacts the lines of resistance and
system stability.

Assumptions
This study was based on the following premises:
1.

Onychomycosis can be accurately diagnosed without

verification of mycology.
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2. Onychomycosis is a painful soft tissue condition
that is expensive to treat.
3. The condition of onychomycosis is a disharmony of
the individual lines of resistance.

Purpose of the Study
The purpose of this study was to determine if the use
of Mentholatum is an effective and cost-efficient means to
treat onychomycosis of the toenails in elders.

Statement of the Problem
Onychomycosis can be the cause of pain,
injury,

soft tissue

and infection and can have an effect on gait due

to discomfort.

The results from the use of Mentholatum in

treating onychomycosis is unknown. A review of the
literature has revealed no research on this treatment.
Also,

there are cost implications when compared to mouth

prescriptive medications.

Research Hypothesis
The null hypothesis was stated as follows:

There is

no effect on onychomycotic toenails in elders treated with
Mentholatum ointment.
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Definition of Terms
For the purpose of this research,

certain terms

required definitions relating to their function within the
study:
Mentholatum: an ointment with active ingredients of
camphor at 4.8% and Menthol at 2.6%.

The operational

definition for this study was Mentholatum is an over-thecounter ointment with the active ingredients of camphor at
4.8% and Menthol at 2.6%.

The over-the-counter drug used

was Vicks Vaporub®.
Onychomycosis:

a chronic fungal or yeast infection of

the nail bed with involvement of the nail plate.

The

operational definition for this study was onychomycosis is
a chronic fungal condition of the toenail as diagnosed by
the attending physician.
Elder: an adult whose age ranged from 60 to 100
years.

The operational definition of elder was an adult

who is a resident of a nursing home and has been diagnosed
with onychomycosis of the toenail.

Summary
Onychomycosis can affect 2% to 18% of the population,
with a higher incidence in the elderly,
positive.
cure.

diabetics,

and HIV

It is a chronic disease and can be difficult to

Onychomycosis can cause soft tissue injury which can
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lead to infection.

Current oral medications are costly and

pose risks of serious side effects.

The Neuman Systems

Model was used as the theoretical framework.

The

hypothesis of this study was that there is no effect on
the onychomycosis of the toenails in elders treated with
Mentholatum.

The purpose of this study was to determine if

the use -of Mentholatum ointment is an effective and costefficient means to treat onychomycosis of the toenails in
elders.

Chapter II
Review of the Literature

To determine the current status of research regarding
the treatment of onychomycosis,
conducted.
study.

a review of literature was

Five research articles were reviewed for this

Syed,

Qureshi,

Ali,

and Ahmed

(1999)

examined the

efficacy of butenafine and 5% Melaleuca alternifolia in
the treatment of onychomycosis.

Lebwohl et al.

(2001)

examined the safety and efficacy of terbinafine as a
treatment.

Smith,

Stein,

Fivenson,

and Atillasoy

(2000)

examined the safety of terbinafine in patients who were
over the age of 60 years,

de Ocariz et al.

(2001)

examined

the frequency of onychomycosis in patients with chronic
venous insufficiency who had cutaneous manifestations.
Baran et al.

(2000)

reported on the effects of treating

onychomycosis with a combination therapy of amorolfine 5%
solution nail lacquer and oral terbinafine with
terbinafine alone.
Syed et al.

(1999)

studied the efficacy and

t o 1erability of 2% butenafine and 5% Melaleuca
alternifolia stated in a topical cream as a treatment for
12
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onychomycosis.

Syed et al.

(1999)

stated that 30% of all

mycotic infections are the chronic disease of
onychomycosis.

Onychomycosis is both difficult to diagnose

and treat because the parasitic infection can build an
effective barrier to the penetration of antimycotic agents
when located in dead keratinized tissue,
toenail.

Butenafine was defined as an antimycotic

fungicidal,
(p. 285).

such as the

a "pheno-substituted benzylamine derivative"

The other active agent of the cream, Melaleuca

alterni folia f was defined as an essential oil which
contained "terpinen 4-ol,
285).

cheole and viridiflorene"

(p.

Onychomycosis was defined as the clinical diagnosis

of at least a 25% involvement of one of the great toenails
by a fungal infection,
culture.

which was confirmed by a positive

Clinical success was defined as 100% remission or

a 90% to 99% improvement in the treated toenail.
Mycological cure was defined as a negative fungal culture,
utilizing a wet potassium hydroxide
Syed et al.

(1999)

(30%) test.

used a randomized,

placebo-controlled study.

double-blind,

The population for the study was

obtained by referrals from medical officers or registered
medical practitioners.

The officers and practitioners had

been informed by the researchers that pregnant and
lactating women were not candidates for enrollment in the
study.

The sample was obtained by a baseline screening
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process which excluded subjects by specified criteria.
These criteria included:
Onychomycosis caused by molds, bacteria or Candida
sp p. , a history of psoriasis, any serous concurrent
disease, hypersensitivity to Melaleuca alternifolia
oil, azole or benzylamine derivatives and concomitant
therapy with drugs appearing to affect the
bioavailability of benzylamine . . . patients who had
received systemic antifungal treatment within the
previous three months or who were using topical
treatment the two weeks preceding the study were not
enrolled, (p. 285)
The sample

(N = 60)

included 31 males and 29 females.

Their ages ranged from 18 years to 80 years,
of 29.6 years.

In the sample group,

48.3% were diagnosed

with onychomycosis less than one year,
diagnosed for one to 3 years.

with a mean

and 51.7% had been

Thirteen subjects had used

systemic medication longer than one year prior to the
study,

and 12 subjects had used topical treatment in the 6

months preceding the study.
The researchers followed the Helsinki declaration
recommendations for informed consent. All 60 subjects gave
consent for treatment.

The subjects were then randomly

assigned to either the treatment group or the control
group.

Randomization was affected by the subject receiving

a precoded tube of cream.
both agents,

The active tube would contain

while the placebo would contain only the 5%

Melaleuca alte rn if ol ia . There were 40 active tubes and 20
placebo tubes.

The study protocol limited active treatment

15
to 8 weeks.

The groups were comparable statistically for

the area of toenail infected as well as age and race.

The

subjects were instructed by the researchers in the three
times a day application of the cream and application of an
occlusive dressing. All subjects were determined to be
compliant with the treatment and were included in the
efficacy analysis.
The efficacy,

tolerability of the cream,

and overall

success of the treatment were determined by weekly
examination.
8, 24,

Also,

laboratory cultures obtained at weeks

and 36 were included in the evaluation.

examination,

a determination was made if the toenail was

ready for debridement.
clipper.

At 4 weeks,

Debridement was done with a nail

4 males and 5 females had treated

nails which were debrided;
females'

Upon

at 5 weeks,

treated nails were debrided.

9 males and 4
Seven males and 3

females were debrided after 6 weeks.
At the end of the study,
Syed et al.

(1999)

the code was broken,

and

discovered that all 32 of the debrided

nails were from the active group.

The researchers utilized

the Cochran-Mantel-Haenszel test to compare the "clinical
effectiveness and overall success of treatment"
between the active and placebo groups.

(p. 285)

To determine if

there was homogeneous between treatment and cure,
researchers used the Breslow-Day test.

the

To compare the
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relationship between treatment and outcome,

the

researchers used the Fisher's two-tailed test.

Causative

dermatophytes were determined by laboratory culture.
this study.

In

Trichophyton ruhrum was isolated in 93.3% of

the subjects.

Trichophyton tonsurans in 5%, and

Trichophyton memtagrophytes in 1.7% of the subjects.
In the active group,
inflammation.

4 subjects reported mild

The inflammation was not severe enough to

interrupt treatment.

The result was that 93.3% of the

subjects experienced no side effects.
At 36 weeks,

an overall cure rate for the active

group was 80%, while the placebo group's overall cure rate
was negligible

(p < .0001).

Reported relapses in the

active group after one year was negligible.
The researchers concluded that this treatment,
compared with systemic antimycotic treatment,
"significantly better"

(p. 286).

the result of an 80% cure rate,
reported mild side effects,

Syed et al.

when

was
(1999)

cited

only 6.7% of the subjects

and zero relapse,

while

systemic treatments were "accompanied by precarious drug
related side effects and required long-term regimes to
achieve resolution"

(p. 286).

Syed et al.

found that

Melaleuca alternifolia alone "did not show the expected
response"

(p. 286).

The researchers did not indicate what

response they had expected.

The researchers suggested that
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the application of the placebo treatment for only 8 weeks
was "insufficient to render its full potency"
Syed et al.

(1999)

(p. 285).

concluded that the findings of the

study were that the topical application of 2% butenafine
and 5% Melaleuca alternifolia in cream,
debridement,

was "safe,

along with

tolerable and significantly more

effective than placebo to cure toenail onchycomosis"

(p.

286) .
Syed et al.'s study is germane to this researcher
because it provided insights into some of the components
used to identify a population with a disease process
determination of the sample subjects and tests utilized to
compare and analyze the findings of the two treatment
groups.

This researcher questions the term placebo when

there was an expected response in its application.

In this

researcher's study, patients were similarly excluded if
there was a diagnosis of psoriasis,

had received a

systemic antifungal treatment in the 3 months prior to
beginning the study,

or had received a topical antifungal

treatment in the 2 weeks prior to beginning the study.
In another study Lebwohl et al.

(2001)

stated that

the usual cause of onychomycosis is dermatophytes.
may also be nondermatophytes present.

There

Nondermatophytes

role in onychomycosis is unclear and a "subject of debate
among mycologists"

(p. 359). The purpose of this study was
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to determine terbinafine's efficacy in treating
onychomycosis associated with a combination of
dermatophyte and nondermatophyte or nondermatophyte alone.
The primary efficacy variable was defined by Lebwohl et
al.

(2001)

as effective treatment.

The efficacy variables

were defined as unaffected nail length and nail
involvement at baseline.

The secondary variable was

defined as no nail involvement at 48 weeks and negative
mycology.

Terbinafine was defined as a "synthetic

antifungal agent of the allylamine class"

(p. 359).

Effective treatment was defined as a specimen with both a
negative culture and KOH microscopy and a minimum of 5 mm
growth of unaffected nail to no nail involvement.

Complete

cure was defined as negative mycology along with no nail
involvement.

Isolated nondermatophytes were identified as

A l t e r n a r i a , Asper gi ll us , and Candida.
dermatophyte was "usually"
Lebwohl et al.
double-blind,

(2001)

The isolated

Trichophyton rubrum
used a randomized,

placebo-controlled study.

(p. 358).
multicenter,

The sample

(N =

97) was randomized to the eight study c e n t e r s . There were
32 subjects in the placebo group and 65 subjects in the
treatment groups.
The subjects were both male and female.
ranged from 18 to 70 years.

The ages

The three subject groups

received either terbinafine 250 mg once a day for 24

19
weeks,

terbinafine 250 mg once a day for 12 weeks,

then

placebo for 12 weeks or placebo for 24 weeks.
Evaluation of the target toenails was done before
treatment was initiated,
during treatment.

then at 12,

18, and 24 weeks

Subjects were evaluated every 6 weeks

after treatment was completed up to week 48. Nails were
evaluated for estimated percentage of involved nail,
unaffected length of nail,

and nail growth.

Subjects and

investigators rated the overall effectiveness of
treatment.
In approximately 70% of the subjects,

a mixture of

dermatophytes and nondermatophytes was isolated from the
target nail.

In the remaining subjects,

alone were isolated.

nondermatophytes

Candida was isolated in 33% of the

sample,

9% in the placebo group,

and 23% in the treatment

groups.

In 3 of the 9 subjects of the placebo group and 3

of the 23 in the treatment groups Candida albicans were
identified specifically.
Lebwohl et al.

(2001) based end-of-the-study results

on the "last post-baseline nonmissing observations up to
and including week ninety six"

(p. 359).

If relapse was

detected between weeks 48 and 96, the subjects were no
longer included in the positive category. Adverse events
were reported as similar between the placebo group and the
treatment groups, with 69.2% of the treatment group
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experiencing adverse events versus 65.2% of the placebo
group.

Gastrointestinal complaints of "dyspepsia,

abdominal pain,
treatment group.

and flatulence" were more common in the
In the treatment group 2 0% of the

subjects reported incidents of gastrointestinal symptoms
versus 12.5% of the placebo group subjects.

Reversible

taste abnormalities were also more common for the
treatment groups than for the placebo group.
At the end of the study, Lebwohl et al.

(2001)

identified effective treatment for all isolates in the 12week treatment group to be 67.7%
the 24-week treatment group 63.6%

(21 of 31 subjects),
(21 of 33 subjects),

for the treatment groups pooled 65.6%.

and

Complete cure for

all isolates in the 12-week treatment group was 38.7%
of 31 subjects),

for

(12

for the 24-week treatment group 39.4%

(13

of 33 subjects ), and for the treatment groups pooled
39.1%.

Negative mycology for all isolates in the 24-week

treatment group was 74.2%
week treatment group 72.7%

(24 of 31 subjects),
(24 of 33 subjects),

for the 24and for

the treatment groups pooled 73.4%.
End-of-the-study results for the 12 subjects who were
in the 12-week treatment group who cultured positive for
Candida specifically were as follows:
my cology

(10 of 12 subjects),

(10 of 12 subjects),

83.3% negative

83.3% effective treatment

and 33.3% complete cure

(4 of 12
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s u b j e c t s ) . The results for the 11 subjects who were in the
24-week treatment group and who cultured positive for
Candida specifically were 100% negative mycology
subjects),

81.8% effective treatment

and 54.5% complete cure

(11 of 11

(9 of 11 subjects),

(6 of 11 s u bjects).

End-of-the-study results for the 3 subjects who were
in the 12-week treatment group and who cultured positive
for Alternaria specifically were 100% negative myco log y
of 3 subjects),
subjects),

66.7% effective treatment

and 33.3% complete cure

(3

(2 of 3

(1 of 3 s u b j e c t s ) . The

results for the 5 subjects who were in the 24-week
treatment group who cultured positive for Alternaria
specifically were 40% negative mycology
20% effective treatment

(2 of 5 s u bject s),

(1 of 5 subjects),

and none with a

complete cure.
End-of-the-stay study for the 2 subjects who were in
the 12-week treatment group who cultured positive for
Aspergillus specifically were 100% negative mycology
2 su bjects), 100% effective treatment
and 50% complete cure

(2 of

(2 of 2 su bjects),

(1 of 2 sub je ct s). The results for

the 5 subjects who were in the 24-week treatment group who
cultured positive for Aspergillus specifically were 60%
negative mycology
treatment
subj e c t s ) .

(3 of 5 subjects), 40% effective

(2 of 5 subjec ts) , and 40% complete cure

(2 of 5
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In the end-of-study results for the placebo group,
subjects cultured Candida^

9

6 subjects cultured A l t e r n a r i a ,

and 4 subjects cultured A s p e r g il lu s. There were 7 subjects
who had negative mycology at the end of the study.

There

were no subjects for the effective or complete cure
results.
Lebwohl et al.

(2001)

concluded that receiving

terbinafine for 24 weeks was no more effective than a 12week course.

They also concluded that both regimens were

tolerated well and were safe. The isolation of
nondermatophytes,

other than Candida ^ Alternaria ^ and

A s p e r g i l l u s , was insufficient to allow conclusions to the
efficacy of terbinafine regarding those organisms.
et al.

(2001)

concluded that treatment of onychomycosis,

in which the nondermatophyte species
and Aspergillus)

{Candida ^ A l t e r n a r i a ,

were specifically isolated was similar to

both nondermatophytes and dermatophytes.
(2001)

Lebwohl

Lebwohl et al.

stated further clarification was needed for the

"spectrum of activity and in vivo efficacy of terbinafine"
(p. 360).
The study reviewed was germane to this researcher
because it provided insight into the efficacy and safety
of terbinafine.

If the use of Mentholatum on onychomycosis

shows some efficacy of treatment,

then there is the

potential for comparison of efficacy,

costs,

safety,

and
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adverse events between terbinafine and Mentholatum in the
treatment of onychomycosis.
Smith et al.

(2000)

studied the safety and efficacy

of terbinafine as treatment for onychomycosis of the
toenails in patients older than 60 years.

These

researchers stated onychomycosis of the toenail is a
common disease.

The prevalence of onychomycosis may be 2%

to 8% of the population and even higher for elderly
patients.
Smith et al.

(2000) used an open-label,

multicentered

prospective study to evaluate the safety and efficacy of
terbinafine as a treatment.
study included ".

Criteria for inclusion in this

. . age 60 years or older,

a diagnosis

of onychomycosis confirmed by positive po tassium hydroxide
(KOH) preparation at baseline,
regrowth"

and toenails capable of

(p. 859). Any patient who had received systemic

antifungal therapy 3 months prior to the initiation of the
study or who had received topical antifungal therapy one
week prior to the initiation of the study were excluded.
Also,

any patient with a diagnosis of psoriasis was

immunosuppressed or immunodeficient, had at baseline serum
hepatic enzyme values greater than 1.5 times normal upper
limits,

or any toenail abnormalities which interfered with

normal toenail appearance were excluded.
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At the conclusion of baseline evaluations,

those

patients who were eligible were given a 12-week supply of
terbinafine 250 mg to be self-administered on a once-a-day
dose schedule.
12,

24,

36,

Follow-up evaluations were conducted at 6,

48, and 72 weeks.

Safety was assessed at baseline by physical
examination and laboratory evaluations of hematology,
blood chemistry,

and urinalysis. At weeks 6 and 12,

safety

and tolerance were assessed by physical examination and a
repeat of the laboratory evaluations. All follow-up visits
included assessment of the extent of target toenail
involved and "global assessments of therapeutic efficacy"
(p. 860)

as well as reporting of any adverse event

experienced by the participant.
The sample

(N = 30) evaluated for safety included 22

males and 8 females,
mean of 67.6 years.

ages 61 years to 84 years,

with a

The sample population was Caucasian.

The duration of current episode of onychomycosis was 24
months to 552 months,

with a mean of 210.4 months.

The sample evaluated for efficacy included 13 males
and 2 females.
years,

Their ages ranged from 61 years to 7 9

with a mean of 66.8 years. All of the sample

population were Caucasian.

The mean duration of the

current episode was 186.4 months,
months to 552 months.

with a range of 24
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For both samples,

over half of the population had

been treated previously for onychomycosis.

Prior treatment

therapies included systemic and topical antifungal
therapies and nail avulsion.
Patient compliance was defined as at least 80% use of
the terbinafine.

This use was assessed by tablet counts at

weeks 6 and 12. The mean compliance to the safety
population was 98.5% at 6 weeks and 98.0% at 12 weeks.
Mean compliance was not given for the efficacy population.
No study participants in the safety group withdrew
because of adverse events.
(96.7%)

Twenty-nine participants

completed the course of antifungal treatment,

27 participants

(90%)

and

completed follow-up through week 27.

No serious adverse events or deaths were reported during
the period of study. Mild or moderate adverse events
reported during the treatment period were transient.
Investigators "attributed a possible,

probable,

or

definite causal relationship between an adverse event and
the study drug in 13 patients"
patients,

(p. 860). Of the 13

there were 18 reported adverse events.

These

events included gastrointestinal system disorders,
disorders,

respiratory disorders,

skin

and central and

peripheral nervous system disorders. Although reported in
other studies of terbinafine,

there were no reports of

taste or ocular disturbances in this study.
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Twenty-eight participants

(93.3%)

received

concomitant medication during the treatment.

The

medications were both prescription and over-the-counter.
The most common prescription medications were
cardiovascular agents.

The prescription medications

included ACE inhibitors,

beta blockers,

blockers,

diuretics,

estrogen,

organic nitrates,

sulfonamides.
acetaminophen,

calcium channel

benzothiazepine derivatives,
thyroid hormones,

and

The over-the-counter medications included
aspirin,

NSAIDS,

expectorants,

and vitamin

and mineral supplements.
Terbinafine is "metabolized by at least seven
isoenzymes of the P-450 system"
participants,

(p. 863). Of the 30

16 were concomitantly taking medications

that were metabolized by the P-450 system.

There were no

reported interactions between these medications and the
terbinafine.
Of the efficacy population,

only one did not complete

the study. At week 72 or the last observation,

46.7% of

the patients experienced cure. Mycological cure did not
fall below 92.9% after week 24. Ten of the remaining 14
participants reported at the end of the study to be
"satisfied or very satisfied" with the appearance of the
target nail.
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As the increase of the elderly population continues,
the significance of medical and quality of life issues of
onychomycosis will continue for this population.
al.

(2000)

Smith et

concluded that in the presence of concomitant

drug therapies systemic terbinafine can be used safely and
effectively to treat onychomycosis of the toenail in the
elderly.
Smith et al.'s

(2000)

study is germane to this

researcher because it identified frequently used
medications,

both prescription and over-the-counter,

utilized by the elderly population and the safety of
concomitant systemic terbinafine therapy.
In the study by de Ocariz et al.

(2001),

the

researchers stated that the prevalence of chronic venous
insufficiency is high,

especially in the elderly.

Chronic

venous insufficiency represents 1% to 6% of all general
d e rmatological consultations.

The cutaneous manifestations

of chronic venous insufficiency may also be termed as
venous leg ulcer or cutaneous vascular complex of the leg.
These manifestations are divided into three grades of
severity.

Grade 1 is the presence of edema,

the presence of hyperpigmentation,
presence of an ulcer.

grade 11 is

and grade 111 is the

The purpose of this study was to

determine the frequency of nail pathology and
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onychomycosis in those patients with cutaneous
manifestations of chronic venous insufficiency.
Onychopathy may originate because of vascular
abnormalities such as arterial insufficiency or diabetes
mellitus and others.

The determination of the etiology of

nail changes may be difficult due to the limited number of
reactive patterns of the nail when affected by disease.
de Ocariz et al.
observational,

(2001)

used a prospective,

and transversal study.

The sample

{N = 36)

consisted of patients examined by a physician at the
dermatology department and were determined to have venous
leg ulcers.
(83.33%)

Thirty of the participants were female

and 6 participants were male

(16.67%).

age of the sample population was 46.39 years.

The mean

Because

previous studies reported relationships between age and
other systemic diseases,

de Ocariz et al. excluded

participants who were over 59 years of age or had other
systemic diseases.
A dermatologist examined all participants,
venous ulcers,

and described the nail changes.

graded all
Mycological

examinations by KOH and culture were performed on all
patients.

Functional studies were performed on 27 of the

36 participants to classify the venous insufficiency as
superficial or deep.
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Venous leg ulcer classification results were 10
participants
(33.33%)

(27.77%)

had grade I, 12 participants

had grade II, and 14 participants

grade III.

had

Fourteen participants were identified with

superficial venous insufficiency;
severity,

(38.88%)

6 of whom had grade I

5 had grade II, and 3 had grade III. Thirteen

participants were identified with deep venous
insufficiency;
II severity,

2 of whom had grade I severity,

3 had grade

and 8 had grade III. While no statistically

significant relationship was identified between the
presence of nail changes and cutaneous disease,
participants with deep venous insufficiency exhibited nail
pathology more frequently.
Nail alterations were found in 22
participants.

Thirteen

(59.09%)

(61.11%)

of the

of the participants were

identified with onychomycosis by mycologie culture or KOH.
Fungi could not be identified in the remaining 40.91% of
the participants.
onychomycosis,
follows:

Of those participants diagnosed with

the venous leg ulcer classification was as

3 participants

(23.07%)

had grade 11, and 6 (46.16%)

had grade 1, 4 (30.77%)

had grade 111. Even though

there was increased frequency of onychomycosis of the
participants with more severe cutaneous disease,

there was

no statistically significant difference between the
groups.
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de Ocariz et al.

(2001)

reported clinical features of

nail changes to be similar for the mycotic and nonmycotic
groups:

color changes

group 88.88%),
84.61%,

(mycotic group 100%,

nail plate thickening

nonmycotic group 55.55%),

(mycotic group 76.92%,
subungual keratosis

nonmycotic

(mycotic group

nail plate opacity

nonmycotic group 44.44%),

(mycotic group 69.23%,

and

nonmycotic

group 33.33%).
de Ocariz et al.

(2001)

concluded nail pathology was

related more to vascular affection than to the severity of
cutaneous affection.

These researchers also identified a

higher incidence of onychomycosis in this study population
than had been reported in the literature for the diabetic
or general dermatological population.
de Ocariz et al.'s

(2001)

study is germane to this

research in that it provided insight into the relationship
of nail pathology and vascular affection.

The co

morbidities of cutaneous affections and diagnosed vascular
diseases were considered in this researcher's study.
The purpose of the study conducted by Baran et al.
(2000)

was to compare the treatment of onychomycosis with

the combination therapy of terbinafine and amorolfine and
terbinafine alone.

Like terbinafine,

amorolfine inhibits

ergosterol production by interference of the 14-reductase
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and 7 , 8-isomerase stages.

Baran et al. also evaluated the

cost per cure ratios.
Baran et al.
randomized,

(2000)

prospective,

utilized a multicentre,
open study.

Inclusion criteria

were severe dermatophyte toenail onychomycosis with matrix
region involvement,

ambulatory adult,

presence of

dermatophytes confirmed by mycology,

and normal liver

function at assessment.

{N = 147)

The subjects

randomized to one of three groups.

were

Group 1 received

terbinafine 250 mg daily for 6 weeks and applied 5%
amorolfine nail lacquer weekly for 15 months.

Group 2

received terbinafine 250 mg daily for

12 weeks and applied

5% amorolfine nail lacquer weekly for

15 months.

the control group,

Group 3,

received terbinafine 250 mg daily for

12 weeks.
Baseline characteristics for treatment group
were as follows:

gender

mean age of 4 6.9 years,
years,

66%;

17 females,

34%),

duration of onychomycosis was 9.1

and interval since last antifungal treatment was

22.6 months.
2

(33 males,

(n = 50)

Baseline characteristics for treatment group

(n = 48) were as follows : gender

females,

(21 males,

56%), mean age of 47.2 years,

onychomycosis was 10 years,

44%,
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duration of

and interval since last

antifungal treatment was 22.1 months.

Baseline

characteristics for treatment group 3

(n = 49) were as
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follows:

gender

of 46.7 years,

(29 males,

59%;

20 females,

41%), mean age

duration of onychomycosis was 9.7 years,

and interval since last antifungal treatment was 26.2
months.
Subjects were assessed by investigators at inclusion,
6 weeks,

3 months,

and every 3 months to month 18. Nail

sampling was done at the inclusion visit and at 3 months.
A single reference laboratory was utilized for all
mycological testing.

Liver function tests were performed

mon thly while the subjects were receiving terbinafine.
Success was defined as a negative result on
mycological testing.

Cure for the combined therapy group

was classified only if subjects were clinically and
mycol ogically clear.

If subjects of this group were not

discovered to be clear,
In the other two groups,

they were classified as failures.
success was defined as no

remaining lesion on the nail or no greater than 10% of
residual disease of the nail.

Failure was defined as less

than a 20% reduction of total diseased nail surface.
Fifty percent of group 1 subjects,

68.8% of group 2,

and 42.9% of group 3 completed the study.

The two primary

reasons for subjects withdrawing from the study were
adverse events and lack of clinical response.

In group 1,

4 subjects withdrew for adverse events and 13 for
inefficacy of treatment.

In group 2, 4 subjects withdrew
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for adverse events and 3 for inefficacy of treatment.

In

group 3, 4 subjects withdrew for adverse events and 16 for
inefficacy of treatment.
treatment.

There were no deaths related to

The most common adverse events included

abdominal pain,
modifications.

nausea,

urticaria,

and liver function

The four subjects who presented with

abnormal liver function were withdrawn from the study.
all three groups,

In

the adverse events related to the

treatment were highest during the first 6 weeks.
A comparison of cost-per-cure ratio was also
evaluated

(costs were reported in French franc

group 1, effectiveness 44%,
cure ratio margin 196.92;
72.3%,

[FF]): For

cost 1118.20 FF, and cost-per-

for group 2, effectiveness

cost 1677.90 FF, cost-per-cure ratios mean 1571.55

FF.
Baran et al.
trials,

(2000) pointed out,

unlike most previous

the subjects of this study were deliberately

selected because of nail matrix involvement.

"These

infections are generally considered to be the most
difficult to cure"
study,

(p. 1182). At the end of the 18-month

75.7% of the remaining subjects had, by mycological

testing,

no remaining infection.

Baran et al.

(2000)

concluded that "substantial synergy may be generated by
the combination of terbinafine and amorolfine in the
treatment of severe toenail onychomycosis"

(p. 1178).
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Lebwohl et al.

(2001)

found a 12-week course of oral

terbinafine was both safe and efficacious in the treatment
of onychomycosis.

The researchers also found terbinafine

was well-tolerated.

Smith et a l . (2000)

reported that

terbinafine was a safe treatment choice for patients with
onychomycosis who were over the age of 60 and on
concomitant drug therapy.

Baran et al.

(2000)

reported

that their study results indicated that the combination of
oral terbinafine and amorolfine had substantial positive
effects on the treatment of onychomycosis,
al.

(2001)

patients'

de Ocariz et

discovered nail changes to be common in
cutaneous manifestations of chronic venous

insufficiency and that half of these patients'
changes could be attributed to onychomycosis.
(1999)

nail
Syed et al.

compared efficacy of treating onychomycosis with 2%

butenafine and 5% Melaleuca alternifolia and 5% Melaleuca
alternifolia in a placebo.

While the combination cream was

found to be an effective and well-tolerated treatment for
onychomycosis,

Melaleuca alternifolia alone had little

effect on the disease.

Chapter III
The Method

The purpose of this study was to assess the effects
of Mentholatum on onychomycosis of the toenail in elders.
Research has confirmed that onychomycosis impacts the
overall health and quality of life of those who are
afflicted.

The advanced practice nurse needs to be

cognizant of the impact of onychomycosis and the
treatments available.

With the increase of the use of

complimentary and alternative medicines,

the nurse

practitioner must become an active participant in the
study of their effects and efficacies.

Design of the Study
The p r e - p o s t , quasi-experimental design was utilized
to measure the effects of applying Vick's Vapo rub ® to
onychomycosis of the toenails.

Gillis and Jackson

(2002)

described quasi-experimental design as one which has not
met the requirements for classical experimental design.
this quasi-experimental design,

there was no randomization

of subjects to a control group. Although limited in
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In
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controls,

this design was appropriate in the current study

because it measured the effects of treatment.

Variables
The dependent variable in this study was
onychomycosis of the toenail.

The treatment variable was

application of Vick's Varporub®.

Controlled variables

included the co-morbidities of atherosclerosis,
arteriosclerosis,

peripheral vascular disease,

and

diabetes mellitus.

L i m i t a tions
The population for this study was limited to elders
who reside in a nursing home.

The information of this

study is applicable to the study sample and may not
adequately represent the general population of elders.
addition,
unknown.

In

the therapeutic dosing of Vick's Vapor ub® is
The length of study time may not allow for

adequate treatment time.

Inconsistency in the application

of treatment by nursing home staff may be a limiting
factor.

External validity may be strengthened by nursing

home staff receiving identical instruction,
instruction for reference,

written

and written orders.

37
S e t t i n g , Population^ and Sample
The setting for this study was three nursing homes in
a southern state. All the nursing homes are in rural
communities and have only physician providers.

The

population included all residents of the nursing home.

The

sample consisted of those residents diagnosed with
onychomycosis of the toenail and who,
responsible party,

along with the

signed a consent form for participation

in the study.

Methods of Data Collection
Instrumentation,

The instrument used to collect a

visual recording of treatment effects was a digital
camera.

Data were gathered using four researcher-developed

instruments.
Survey

The first was the Inter-rater Reliability

(see Appendix A) which includes two sections.

The

first section had five photographs of onychomycosis
toenails.

The second section asks for panel member's

determination of severity of onychomycosis for each
photograph.
Survey

The second instrument was the Demographic

(see Appendix B) which also includes two sections.

The first section has five questions requiring a response
from the panel member.

The second section is provided for

photographic identification,
for four points of treatment.

including a picture and date
The third instrument is the
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Physician Evaluation Survey
includes three questions.

(see Appendix C ) . This

The first two questions require

initial determination of onychomycosis severity and
significant changes on initial states of the nail using
three additional pictures.

The third question is optional

and allows for comment reflecting photographs and nail
appearance.

The fourth instrument is the treatment survey

(see Appendix D ) . On this survey,

the number of treatments

given and omitted were recorded weekly.
P r o c e d u r e . Following approval of the Committee on Use
of Human Subjects in Experimentation at Mississippi
University for Women

(see Appendix E ) , the researcher

contacted the administrators of the three nursing homes by
letter

(see Appendix F ) . The letter requested consent to

conduct the research within the facility. After consent
was obtained,

the researcher in-serviced the nursing staff

on the purpose of the study, method of treatment
application,
application

and significance of consistency of
(see Appendix G ) . Five photographs were

evaluated by the panel to establish inter-rater
relia b i l i t y ) . Then those residents who were diagnosed with
onychomycosis of the toenail by their attending physician
were contacted by the researcher and informed of the study
(see Appendix H ) . Consent was obtained for participation
from the resident and his or her responsible party

(see
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Appendix I ) . Photographs of the affected nail were made
prior to beginning treatment and then orders for treatment
were written on the resident's c h a r t . Photographs of the
affected nail treated were made every 4 weeks after the
initiation of treatment until the study was completed. At
the completion of the study,

the photographs were placed

on the Demographic Survey and the demographic information
entered by the researcher.

The panel members then

completed the Physician Evaluation Survey.

During the

course of the treatment, medication administration records
for each patient were reviewed for missed applications of
treatment.

Data were then submitted to a statistician for

appropriate analysis utilizing a t test and calculation of
statistical percentages and means.

The inter-rater

reliability was determined by utilizing correlations and
percentages.

The Demographic Survey was analyzed utilizing

percentages and correlations of the frequency of the co
morbidities and presence of onychomycosis.

Chapter IV
The Findings

The purpose of this study was to determine if the use
of Mentholatum was an effective and cost-efficient means
to treat onychomycosis of the toenail in elders.
design was pre-post,
null hypothesis.

The

quasi-experimental to address the

The hypothesis stated there would be no

effect on the onychomycosis of the toenail.

In this

chapter the sample and analysis of the data will be
described in relation to the hypothesis.

Description of the Sample
Purposive sampling was utilized for collection of
data from nursing home residents.

The residents were from

three nursing homes in a small town in a southern state.
Attending physicians identified those residents diagnosed
with onychomycosis.
party,

The residents and their responsible

who signed a consent form for participation,

comprised the sample.

Forty-one residents began the study.

Thirty-two residents continued to participate until
completion of the study.

The final sample consisted of 32
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residents who had signed a consent form and received
treatments for 72 days.

Demographic Data
Demographic data were collected for all participants
in regard to age,
atherosclerosis,
disease,

gender,

race,

and co-morbidities of

arteriosclerosis,

peripheral vascular

and diabetic mellitus. All subjects

residents in one of three nursing homes.
from 65 years to 96 years.

{N = 32) were

The ages ranged

The mean age was 83 years.

The

remainder of the data regarding the sample's demographics
ma y be seen in Table 1.

Table 1
Demographic Characteristics of the Sample Expressed in
F requency and Percentage

Variable

Age

f^

%

2
2
1
3
1
3
4
1
3

6.3
6.3
3.1
9.3
3.1
9.3
2.5
3.1
9.3

(years)
65
67
77
80
81
82
83
84
85

{table continues)
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Table 1 (continued)

Variable

%

86
87
88
89
90
94
96

1
2
2
2
2
1
1

3.1
6.3
6.3
6.3
6.3
3.1
3.1

12
20

37 .5
62.5

1
31

3.1
96. 9

3
7
10
17

9.3
21.9
31.2
53.1

Gender
Male
Female
Ethnic origin
African American
Caucasian
Co-morbidity
Atherosclerosis
Arteriosclerosis
Peripheral vascular disease
Diabetes mellitus

Note.

Only subjects who completed the study are reported

= 32.

Inter-rater Reliability
Inter-rater reliability was assessed by having the
raters-doctors independently rate the severity of five
photographs on a 5-point Likert scale.
measurements were obtained,

Once these

an intraclass correlation
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coefficient was calculated to provide an estimate of the
reliability of observational coding.

In short,

an

intraclass correlation is a reliability measurement that
measures the extent to which all raters mean exactly the
same thing by their rating

(Sattler,

1992).

The intraclass

correlation coefficient estimate for the raters used in
this study was

.90, with a two-sided 95% confidence

interval from .67 to .99. This is considered to be an
acceptable level of inter-rater agreement according to
Sattler

(1992) .

Level of Onychomycosis Pre-treatment
In general,

physician ratings indicated that the mean

level of onychomycosis severity before the use of
Men tholatum ointment was M = 3.85.

Based on the 5-point

Likert scale utilized in this study,

a mean of 3.85

indicates that the average level of onychomycosis severity
for the 32 subjects prior to the administration of
Men tholatum ointment was judged to be moderately severe,
while a standard deviation of .96 indicates that the
majori ty of severity ratings lie within the moderate to
severe range.

The remainder of the data regarding the

level of onychomycosis may be seen in Table 2.
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Table 2
Percentages of Subjects within each level of Pre-treatment
Severity Index

Level of pre-treatment

f^

%

Minimal

0

0.0

Slightly Moderate

4

12.5

Moderate

8

25.0

Moderat ely severe

9

28 .1

11

34 .4

Severe

Note.

Percentages were rounded to the nearest 10^^.

^N = 32.

Level of Onychomycosis Post-treatment
Following the administration of Mentholatum ointment,
the average physician rating of change for the subjects
was M = 2.45.
this study,

Based on the 4-point Likert scale used in

a mean of 2.45 indicates that the average

level of change after the administration of the ointment
was judged to fall between minimal change and new nail
growth range

{SD = .59).

Most of the subjects of this

study had a moderate to severe level of onychomycosis
before treatment and that the level of change following
the Mentholatum ointment was deemed to be minimal to
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moderate with signs of new nail growth.

Ninety percent of

the subjects of this study did experience a change of some
degree in the growth and appearance of the nail.

The

remainder of data regarding the level of onychomycosis
post-treatment may be viewed in Table 3 and Figures 1 and
2.

Table 3
Percentages of Subjects Within Each Level of Post-Treatment
Onychomycosis Change Rating by Pre-Treatment Severity Index

Minimal
change

No
change

Normal
nail
growth

New nail
growth
f

%

f

Level

f

%

f

%

Slightly
moderate

0

0. 0

4

100.0

0

0. 0

0

0 .0

Moderate

1

12.5

3

37 .5

5

50.0

0

0.0

Moderately
severe

1

11.0

2

22.0

6

67 .0

0

0.0

Severe

1

9.0

3

27.0

7

64.0

0

0.0

Note. N = 32.

%

Percentages were rounded to the nearest 10^*^.
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In order to assess if those individuals who
experienced no or minimal change were significantly
different from those individuals who experienced moderate
change in terms of pre-treatment onychomycosis ratings,
two-sample t test was conducted.

a

This analysis revealed

that those individuals who were rated as demonstrating new
nail growth

(n = 17, M = 4.02)

had higher levels of

onychomycosis ratings before treatment than those
individuals who demonstrated no change to minimal change
{n = 15, M = 3.43),
(t = 1.78;

although not to a significant degree

a = .05 t w o - t a i l ) .

Summary
Ninety percent of the subjects demonstrated some
change in the nail growth.
the nail growth

Three subjects had no change in

(M = 9.37).

change in the nail growth

Twelve subjects had minimal

(M = 37.5).

subjects had new nail growth

Seventeen of the

(M = 53.12).

Chapter V
The Outcomes

Onychomycosis is the most commonly encountered nail
disease.
pain,

The thickened,

discomfort,

dystrophic nails can result in

soft tissue injury,

Higher prevalence of the disease,

and infection.

those age 60 years and

older and in the immunocompromised,

place these

populations at greater risk if the complications of
onchomycosis develop.

The purpose of this study was to

determine if the application of Mentholatum ointment to
the onychomytotic toenail of elders would affect nail
growth.

With the utilization of complementary and

alternative medicines on the rise in the United States,
the nurse practitioner should be able to give
knowledgeable information regarding their safety and
efficacy.

The Neuman Systems Model was the theoretical

framework for the study. Neuman

(1982)

identified three

levels of intervention for a systematic approach when
stressors have impacted one's lines of resistance.
The researcher utilized a pre-post,
experiment a 1 design.

quasi

The severity of pre-treatment
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onychomycosis was measured on a 5-point Likert scale.
Following a course of treatment,

the effect on nail growth

was measured on a 4-point Likert scale.

The null

hypothesis stated there would be no effect on onchomycotic
toenails in elders treated with Mentholatum ointment.
The setting for the research was three nursing homes
in a small town in a southern state.

The 32 subjects

ranged from 65 to 96 years.
In this chapter the findings,

as well as the

conclusions reached by the researcher,

will be discussed.

The implications of the research for nursing science,
limitations of the study,

the

along with recommendations for

further research will be set forth.

Summary and Discussion of the Findings
Findings from this study,

regarding the effects of

Mentholatum on onychomycosis of the toenail,

showed a

significant change in nail growth post-treatment.

Ninety

percent of the subjects showed some nail growth change.
The sample population was residents of three nursing
homes in a southern state.
study.

Forty-one subjects began the

The reasons for subjects being withdrawn were the

following:

subject request to be withdrawn;

hospitalization,

where treatments were omitted;

n o n c om pliant to treatment reg i me n; and deaths,

subject
which were

50
unrelated to the treatment.

The 32 subjects who completed

the 72 days of treatment application comprised the final
sample population.

The mean age was 83 years.

12 males and 20 females.

There were

Thirty-one of the subjects were

Caucasian and one was Afri ca n- Am er ic an .
There were 4,577 total applications of the twice-aday treatment for the subject population.
m issed treatments,

There were 31

for a mean of less than 1%. The causes

for missed treatment were unknown.
Interrater reliability was established by having the
raters independently rate the severity of five photographs
of omchomycotic nails on a 5-point Likert scale.

The

intraclass correlation coefficient estimate for the raters
used in this study was

.90, with a two-sided 95%

confidence interval from .67 to
The raters,

.99.

utilizing a 5-point Likert scale,

indicated the severity of pre-treatment onychomycosis in
the subject population.

The level of onychomycosis

severity before the use of Mentholatum ointment was judged
to be moderately severe

(M = 3.85), while a standard

deviation of .96 indicates the majority of severity
ratings lie within the moderate to severe range. At the
end of the treatment course,
Likert scale.

the raters utilized a 4-point

The average physician rating of change for

the subjects was M = 2.45

{SD = .59). The mean of 2.45
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indicates the average level fell between minimal change
and new nail growth. A two-sample t test was conducted to
assess if those individuals who experienced no or minimal
change were significantly different from those individuals
who had experienced moderate change.

This analysis

revealed that those individuals who demonstrated new nail
growth

(n = 17, M = 4.02)

had higher levels of

onychomycosis rating before treatment than those
individuals who demonstrated no change to minimal change
{n = 15, M = 3.43),

although not to a significant degree

(t = 1.78; p = .09, a = .05). This pattern of results
tends to indicate that those who had greater onychomycosis
symptomatology pre-treatment tended to display more new
nail growth than those subjects with less severe
onychomycosis.

This pattern can be interpreted as change

is easier to detect with more severe onychomycosis.

Conclusions
Based on the findings of this study,

the following

conclusions were drawn:
1. The application of Mentholatum to onychomycosis of
the toenail in elders positively affected the
growth of the nail.
2. The subjects who demonstrated new nail growth had
a higher level of onychomycosis p r e - t r e at me nt ,
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than those subjects who had no change to minimal
change.

Significance for Nursing
A number of implications for nursing science were
derived from the study. Addressed are implications for
nursing practice,

education,

and research.

P r a c t i c e . Findings indicated the use of complementary
and alternative medicines can and do impact treatment
options for the clients of nurse practitioners.

In order

to provide accurate counseling to clients about those
treatment options,

the nurse practitioner must be aware of

current complementary and alternative medicine practices
and their efficacy.

Because nurse practitioners are

recognized as a professional health care resource,

clients

should be able to rely on the nurse practitioner for a
holistic approach to their care. The nurse practitioner
can provide secondary and tertiary interventions once the
diagnosis of onychomycosis has been made by collaborating
with the client on the most appropriate treatment and
establishing realistic,

obtainable goals for an optimal

state of well-being.
E d u c a t i o n . Schools of nursing at all levels should
include educational opportunities on complementary and
alternative medicines. All practicing nurses could
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encounter clients who may be utilizing complementary or
alternative medicines.

The nurse must be aware of how

complementary or alternative medicines may impact the
client or how they may interact with conventional medical
treatment regimens. All nurses,
experienced,

whether a student or

need educational opportunities to remain up-

to-date with current complementary and alternative
medicines.
R e s e a r c h . Findings from this study indicate that the
use of Mentholatum may have an impact on onchomycosis.
Additional research needs to be conducted to determine to
what degree the treatment will ultimately affect the
disease.

Further studies of the long-term use of

Mentholatum are needed to determine the potential for cure
of onychomycosis.

This researcher also recommends study of

younger aged populations and the response to the
application of Mentholatum to onychomycosis of the finger
nail.

Limitations
The design of the study imposed a number of
limitations that constrained the conclusions drawn from
the research.

The study was limited to elders who resided

in a nursing home, which may limit generalization to
elders who reside outside an institutional setting.

The
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inclusion of only elders in the study further limited the
ability to generalize to other populations of different
ages.

The sample was purposive to a quasi-experimental

design,

which contributed to a weaker design than if a

randomized experimental design was used.
Further limiting the study was the time between
treatment onset and the conclusion of data collection.

The

length of time did not allow for completion of a toenail
growth cycle.

Therefore,

no conclusion could be made

regarding the potential for overall nail appearance to
improve of the possibility for mycologie cure.

The total

size of the sample population limits to some degree the
generalization of the study than a study of a large sample
population.

Recommendations for Future Research
The researcher made the following recommendations for
future research based on the findings from this study:
1. Replication of the study that allows data
collection for the length of a full toenail growth
cycle.
2. Conduction of an experimental study of elders
outside an institutional setting.
3. Conduction of an experimental study of different
age populations.
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4. Conduction of an experimental study of the effects
of Mentholatum on onychomycosis of the fingernail.

REFERENCES

56

57

References

Baran, R . , Feuilhade, M . , Datry, A. Goettmann, S.,
Pietrini, P., Viguie, C ., Badillet, G., Larnier, C .,
& C z er ni el ew sk i, J. (2000) . A randomized trial of
amorolfine 5% solution nail lacquer combined with
oral terbinafine compared with terbinafine alone in
the treatment of dermatophytic toenail onychomycoses
affecting the matrix region [Electronic v e r s i o n ] .
British Association of Dermatologists ^ 142, 11771183.
Bending, A. (2002). Fungal nail infections : Far more than
an aesthetic problem [Electronic v e r s i o n ] . British
Journal of Community Nursing^ 7, 254-259.
de Ocariz, M ., Arenas, R . , Ranero-Juarez, G . , &
M o n r o y -R am os , E. (2001). Frequency of toenail
onychomycosis in patients with cutaneous
manifestations of chronic venous insufficiency
[Electronic v e r s i o n ] . International Journal of
Dermatology ,r 40, 18-25.
Drake, L. A. (1997). Impact of onychomycosis on quality of
life [Electronic v e r s i o n ] . Journal of American
Podiatry Medical Association, 87, 507-511.
Gillis, A., & Jackson, W. (2002). Research for nurses:
Methods and interpretation. Philadelphia: Davis.
Gupta, A. K. (2002). Treatment of dermatophyte toenail
onychomycosis in the United States: A
pharmacoeconomic analysis [Electronic v e r s i o n ] .
Journal of American Dermatology, 92, 272-28 6.
Gupta, A. K. , Jain, H. C ., Lynde, C. W . , MacDonald, P.,
Cooper, E . A . , & Summerball, R. C. (2000). Prevalence
and epidemiology of onychomycosis in patients
visiting physicians' offices : A multicentered
Canadian survey of 15,000 patients [Electronic
v e r s i o n ] . Journal of American D er ma t o l o g y , 43, 244248.

58
Gupta, A. K. , Konnikov, N., & MacDonald, P. (1998) .
Prevalence and epidemiology of toenail onychomycosis
in diabetic subjects: A multicenter survey
[Electronic v e r s i o n ] . British Journal of D e r m a t o l o g y ,
139, 665-671.
Gupta, A. K. , Lynde, C. W., & Jain, H. C. (1997). A higher
prevalence of onychomycosis in psoriatics with n o n 
psoriatics : A multicentre study [Electronic v e r s i o n ] .
British Journal of Dermatology, 786-789.
Gupta, A. K ., & Ryder, J. (2002, M a y ) . Latest advances in
onychomycosis treatment. Clinical Reviews:
Therapeutic Spotlight, 4-10.
Guttman, C. (2002). Onychomycosis QOL shown in VA
population [Electronic v e r s i o n ] . Dermatology Times,
23, Sll.
Havu,

V., Heikkila, H ., Kuokkanen, K ., Nuutinen, M .,
Ranranen, T., Saari, S., Stubb, S., Suhonen, R . , &
Turjanmaa, K. (2000). A double-blind, randomized
study to compare the efficacy and safety of
terbinafine (Lamisil®) with fluconazole (Diflucan®)
in the treatment of onychomycosis. British Journal of
Dermatology, 142, 97-102.

Heikkila, H ., & Stubbs, S. (1995). The prevalence of
onychomycosis in Finland [Electronic v e r s i o n ] .
British Journal of Dermatology, 133, 699-703.
Lebwohl, M. G ., Daniel, C. R ., Leyden, J . , Mormon, M .,
Shavin, J . , Tschen, E ., Weiss, J . , & Zone, J. (2001).
Efficacy and safety of terbinafine for
nondermatophyte and mixed nondermatophyte and
dermatophyte toenail [Electronic v e r s i o n ] .
International Journal of Dermatology, 40, 358-360.
Neuman, B. (1982). The Neuman systems model.
Appleto n- Ce n tu ry -C ro ft s.

Norwalk,

CT:

Ramano, C ., Massai, L ., Asta, F ., & Signorini, A. M.
(2001). Prevalence of dermatophytic skin and nails
infections in diabetic patients [Electronic v e r s i o n ] .
Mycoses, 44, 83-86.

59
Roberts, D. T. (1992). Prevalence of dermatophyte
onychomycosis in the United Kingdom: Results of an
omnibus survey. British Journal of Dermatology,
126(39), 23-27.
Rodgers, P., & Bassler, M. (2001). Treating onychomycosis
American Journal of Family Physicians, 63, 663-672.
Sattler, J. M. (1992) . Assessment of children
New York: Jerome M. Sattler Publishing.

(3"^^ ed.) .

Schein, J. R ., Cause, D ., Stier, D. M ., Lubeck, D. P.,
Bates, M. M ., & Fisk, R. (1997). Onychomycosis
baseline results of an observational study
[Electronic v e r s i o n ] . Journal of American Pediatric
Medical Association, 87, 512-519.
Smith, E. B ., Stein, L. F . , Fivenson, D. P., & Atillasoy,
E. S. (2000). The safety of terbinafine in patients
over the age of 60 years : A multicenter trial in
onychomycosis of the feet [Electronic v e r s i o n ] .
International Journal of Dermatology, 39, 859-864.
Syed,

T. A., Qureshi, S. M ., Ali, S., & Ahmad, S. A.
(1999). Treatment of toenail onychomycosis with 2%
butenafine and 5% Melaleuca alternifolia (tea tree)
oil in cream [Electronic v e r s i o n ] . Topical Medicine
and International Health, 4, 284-287.

Tomey, A. M ., & Alligood, M. R. (2002). Nursing theorist
and their work (5^*^ ed. ) . St. Louis: Mosby.
White House Commission on Complementary and Alternative
Medicine. (2003, March). 2002 White House Commission
on Complementary and Alternative Medicine Policy,
Executive Summary. Retrieved October 26, 2002, from
http ://www .whccamp.hhs.gov/

APPENDIX A
INTER-RATER RELIABILITY SURVEY

60

61

Inter-rater Reliability Survey
Dr.

#

Date of E v a l u a t i o n

Instructions: Please r e v i e w the s e v e r i t y of the o n y c h o m y c o s i s
of the p h o t o g r a p h s and circle the level of s e v e r i t y m o s t
a p p r o p r i a t e for eac h p a r t i c u l a r photograph.
Photograph #1
#1
Minimal

Photograph #2
#1
Minimal

Photograph #3
#1
Minimal

Photograph #4
#1
Minimal

#2
Slightly
moderate

#2
Slightly
moderate

#2
Slightly
moderate

#2

#3
Moderate

#3
Moderate

#3
Moderate

#3

Slightly
moderate

Moderate

#2
Slightly
moderate

#3
Moderate

#4
Moderately
severe

#4

#5
S evere

#5

Moderately
severe

Severe

#4
Moderately
severe

#5
Severe

#4
Moderately
severe

#5
Severe

#4
Moderately
severe

#5
Severe

Photograph #5
#1
Minimal

APPENDIX B
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Demographic Survey

Demographics of the subject:
1. Subject #:____________
2. Age:___________________
3. Gender
Ü a. Male

Ü

b . Female

4. Race:_________________________
5. Co-morbidities present:
□ a. Atherosclerosis
O b . Arteriosclerosis
□ c. Peripheral vascular disease
O d . Diabetes mellitus

Photographs
#1

(Date)

#2

(Date)

#3

(Date)

#4

(Date)

APPENDIX C
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64

65

Physician Evaluation Survey

Dr. _________________
Date of Evaluation:
Subject #:__________

1. Instructions: Please review the severity of the
onychomycosis of the first photograph and circle the
level of severity most appropriate for this particular
photograph.
#1

#2

#3

#4

Minimal

Slightly
moderate

Moderate

Moderately
severe

#5
Severe

2. Instructions: Please review the subsequent photographs
for nail changes in comparison to the first
photograph. Answer the following only in regard to the
final photograph.
#1

#2

No changes

Minimal
change

#3
New nail
growth

#4
Normal nail
growth

3. Comments regarding the photographs and nail appearance
(optional):

APPENDIX D
TREATMENT SURVEY
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Treatment Survey

1 = All treatment given
2 = Treatments omitted (in parenthesis the number of
treatments omitted)
Week #
Patient
1

2

3

4

5

6

7

8
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Treatment Survey

1 = All treatment given
2 = Treatments omitted (in parenthesis the number of
treatments omitted)
Week #
Patient
9

10

11

12

13

14
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M is s is s ip p i
U n iv e r s it y

Office o f Academ ic A ffairs
Eudora W eliy H a ll
W -B o x 1603
Columbus, M S 39701
(6 62 ) 329 -7 1 42
(662) 329-7141 Fax

for) ^ O M E N

www.muw.edu

A d m ittin g M e n Since 1982

March 3, 2003
Ms. Susan D. Cappleman
c/o Dr. Patsy Smyth
P. O. Box W-910
Campus
Dear Ms. Cappleman:
I am pleased to inform you that the members of the Committee on Human Subjects in
Experimentation have approved your proposed research provided the consent form be amended to
add: "Failure to participate will not affect you in any way. "
I wish you much success in your research.
Sincerely,

VagnK. Hansen, Ph.D.
Provost and Vice President
for Academic Affairs
VH:wr
Mr. Jim Davidson
Dr. Patsy Smyth
Dr. Mary Pat Curtis

Where Excellence is a Tradition
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1850 CR 748
Dumas, MS 38 625
December 2, 2002

Jerry Green, Administrator
Tippah County Nursing Home
1007 City Avenue North
Ripley, MS 38663
Dear Mr.

Green,

I am a graduate student at Mississippi University for
Women in Columbus, MS, pursuing a Master of Science in
Nursing, specializing as a Family Nurse Practitioner. I
expect to graduate in August 2003.
I am requesting permission to conduct a portion of my
research on the effects of applying Mentholatum ointment
to toenails which have been diagnosed with onychomycosis.
Members of your nursing home's medical staff who are in
good standing will make the diagnosis of onychomycosis and
will be participating in the review of the effects of the
Mentholatum. A consent form will be signed by the
residents and the responsible party of that resident.
I am also requesting that Mentholatum be applied twice
daily by your nursing staff. I will supply all the
materials necessary for the application. There will be no
cost to the participants. However, I will be unable to
reimburse the nursing home for the time of the nursing
staff.
I would appreciate your allowing me access to the
residents of the nursing home. If you have any questions
or concerns, please feel free to contact me.
Sincerely,

Susan Cappleman
Attachment:

Consent Form
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Inservice for Nursing Home Staff
M y name is S u san Cappleman. I am a r e g i s t e r e d n u r s e in g r a d u a t e
school at M i s s i s s i p p i U n i v e r s i t y for W o m e n School of Nursing. I
a m d o i n g a s t u d y that will o b s e r v e the e f f ects of a p p l y i n g
M e n t h o l a t u m ointment, s p e c i f i c a l l y V i c k ' s Vap o r u b ® , on the
o n y c h o m y c o s i s of the toenail. This is a fungal i n f e c t i o n that
i n v o l v e s the nail or nail bed. The o r g a n i s m enters the
h y p o n y c h i u m f r o m the s u r r o u n d i n g skin, p r o d u c i n g i n f l a m m a t i o n
w h i c h r e s ults in h y p e r k e r a t o s i s a nd onycholysis. A l t h o u g h
o n y c h o m y c o s i s can be asymptomatic, if sympotomatic, the
thickened, d y s t r o p h i c nail can result in discomfort, pain, soft
t i s s u e injury, a nd infection.
I hav e r e c e i v e d p e r m i s s i o n f r o m n u r s i n g home a d m i n i s t r a t i o n to
c o n d u c t a s t u d y in this facility. O n l y those p a t i e n t s wh o have
g i v e n t h e i r c o nsent a nd the c o n sent from t h eir r e s p o n s i b l e
p a r t y o b t a i n e d will be p a r t i c i p a t i n g in the study.
The a t t e n d i n g p h y s i c i a n will be aware of those p a t i e n t s wh o
hav e c o n s e n t e d a nd w ill a l l o w an order for the a p p l i c a t i o n of
the o i n t m e n t to be written. All the a t t e n d i n g p h y s i c i a n s of
this f a c i l i t y are partic i p a t i n g .
The o i n t m e n t will be a p p l i e d by you, the n u r s i n g staff, twice a
day. Yo u wil l a p p l y o n e - h a l f inch of o i n t m e n t to the d e s i g n a t e d
g r e a t toe or toes. The toe or toes will be i d e n t i f i e d on the
o r d e r a nd the time of a p p l i c a t i o n will be the f a c i l i t y ' s u s ual
b.i.d. d o s i n g schedule.
The o i n t m e n t will be s u p p l i e d b y me for each patient. There
w i l l be p a p e r that is m a r k e d w i t h a 2 - i n c h m e a s u r e w i t h oneh a l f inc h m a r k i n g s to a l l o w for a c c u r a t e d i s p e n s i n g of the
ointment. You will then be able to t r a n s f e r the o i n t m e n t fro m
the p a p e r to the great toe of the resident. L i g h t l y m a s s a g e the
o i n t m e n t onto the nail a n d the s u r r o u n d i n g skin of the nail.
T h e r e is no cost to the patient. The p a t i e n t m a y d e c l i n e to
p a r t i c i p a t e in the study or change his or her m i n d at a ny time
d u r i n g the s t u d y a nd withdraw. His or her d e c i s i o n to d e c l i n e
to p a r t i c i p a t e in the study or to w i t h d r a w from the s t u d y wil l
in no w a y a f f e c t his or her care from the a t t e n d i n g p h y s ician.
It is e s s e n t i a l to the ou t c o m e of this s t udy that the
a p p l i c a t i o n s be c o n s i s t e n t b e t w e e n all the staff wh o a p p l y the
ointment.

APPENDIX H
SCENARIO FOR INTRODUCING THE STUDY
TO RESIDENTS AND THEIR RESPONSIBLE PARTY
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Scenario for Introducing the Study
to Residents and Their Responsible Party

My name is Susan Cappleman. I am a registered nurse in
graduate school at Mississippi University for Women School
of Nursing. I am doing a study that will observe the
effects of applying Mentholatum ointment, specifically
Vick's Vaporub®, on fungal toenails.
Your physician has diagnosed you with a fungal infection
of your toenail. Participation in this study is absolutely
voluntary. If you are not interested in participating, it
will in no way affect your treatment by your physician.
Your name will not be used in any of the results of the
study. 1 will keep your identity confidential if you
should choose to participate. The risk associated with
this study is a possible skin sensitivity to the
Mentholatum. If that should occur, the ointment will be
stopped immediately.
If you are interested in participating, your responsible
party will need to agree to the study as well. I will be
happy to answer any questions you and your responsible
party may have.

APPENDIX I
CONSENT OF RESIDENT AND RESPONSIBLE
PARTY FOR PARTICIPATION IN
INTER-RATER RELIABILITY SURVEY
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Consent for Participation

My name is Susan D. Cappleman. I am a registered nurse in graduate
school at Mississippi University for Women School of Nursing. I am
doing a study that will observe the effects of applying Menthola tum
ointment (Vick's Vaporub®) on fungal toenails. The goal of the study
is to gain knowledge that m ay help future p a t i e n t s .
Participation in the study is voluntary and you have the right to
refuse to participate or you may agree to take part in the study now
and then change your mind. You may withdraw from the study at any time
up to the time analysis of data begins. I cannot promise that this
treatment will benefit you. Declining to participate will in no way
affect your care given by your physician. During the course of the
study, you will not be able to take antifungal medications.
Photographs will be made of the toes. The photographs will be viewed
b y a group of physicians and a podiatrist to measure the effectiveness
of the Mentholatum. All of the results of the study will be reported
as a group, not as individuals. Your identity will be kept
confidential from all parties except me.
The risk is possible skin sensitivity to the Mentholatum. If this
should occur, participation in the study would stop immediately and
would in no way affect your care. There will be no cost to you for
participation. Your regular physician will be m onitoring you
throughout the application of the Mentholatum.
Your participation would require:
1. Carefully reading and consideration of the consent form and to
ask any questions you have before signing the consent form.
2. Al lowing Mentholatum to be applied to the toenail and surrounding
tissue twice a day by the nursing home staff. The estimated time
of the study is 3 months.
3. A llowing photographs of your toes to be made before treatment
begins and each month after until the study is completed.
At the end of the study, you will be informed of the results. If you
have any questions regarding the study, please call me at (662) 8371404. A copy of the consent form can be made available on request.
Your signature will indicate that you have read and understood the
consent form, have had all your questions answered, and have decided
to participate.

Date

Participant's Signature

Date

Responsible Party's Signature

Date

Investigator's Signature

